Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flindokalner
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Flindokalner is a small molecule neuroprotective agent developed by Bristol Myers Squibb. It acts as a positive modulator of potassium channels, with high potency and specificity for the large-conductance calcium‐activated potassium channel (BKCa or SLO1). Flindokalner also positively modulates all neuronal Kv7 channel subtypes. Its mechanism of action involves enhancing potassium ion flow across neuronal membranes, thereby influencing neuronal excitability and providing neuroprotection. The drug was primarily investigated for the treatment of stroke but development was discontinued after reaching phase III clinical trials[5][8][7].
- Brand names
- MaxiPost
- Other names
- flindokalner(3s)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2h-indol-2-one(3s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1,3-dihydro-2h-indol-2-one2h-indol-2-one, 3-(5-chloro-2-methoxyphenyl)-3-fluoro-, 1,3-dihydro-, 6-(trifluoromethyl), (3s)-
02
Targets
KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))
Beyond the preview
Go deeper on Flindokalner.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flindokalner.